Table 5.
Study 3201: Proportion of Patients with Serum Urate Concentrations Above the Upper Limit of Normal by Sex and SLC2A9 Variant rs7442295 Genotype Subgroups.
| Male | Female | ||||
|---|---|---|---|---|---|
| rs7442295 genotype | Iloperidone | Placebo | Iloperidone | Placebo | |
| Baseline, percentage of patients above ULN | GG | 8.3% (1/12) | 14.3% (1/7) | 0.0% (0/7) | 0.0% (0/8) |
| AG | 2.4% (1/41) | 14.9% (7/47) | 7.7% (3/39) | 0.0% (0/36) | |
| AA | 10.0% (6/60) | 13.5% (7/52) | 9.5% (4/42) | 20.1% (10/48) | |
| EOS, percentage of patients above ULN | GG | 33.3% (4/12) | 0.0% (0/6) | 0.0% (0/7) | 0.0% (0/7) |
| AG | 13.5% (5/37) | 15.5% (7/45) | 8.1% (3/37) | 9.7% (3/31) | |
| AA | 12.3% (7/57) | 4.3% (2/46) | 15.0% (6/40) | 14.3% (6/42) | |
Lab-specified ranges of the upper limit of normal (ULN) values of serum urate evaluations in Study 3201 were 453 μmol/L for males and 394 μmol/L for female patients.